Citing irreparable harm and inadequacy of money damages, a Delaware federal judge on Thursday permanently enjoined Sanofi SA and Regeneron Pharmaceuticals from selling a product that infringed on the patents of a rival drugmaker.

The ruling, outlined in a seven-page memorandum order, came just two days after U.S. District Judge Sue L. Robinson of the District of Delaware blocked the defendants’ attempt to throw out a jury verdict upholding the validity of two patents held by Amgen Inc.